Cancer Genetics to Present New Data From Renal Cell Carcinoma Study at AACR Genomic Alterations Identified in Study Could Potentially Serve as Biomarkers for Metastasis in RCC RUTHERFORD, N.J., April 3, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based diagnostics, announced today that a poster highlighting preliminary results of a study in clear cell Renal Cell Carcinoma (ccRCC) will be presented at the 105^th Annual Meeting of the American Association of Cancer Research ("AACR"), which will be held in San Diego, California April 5-9, 2014. Date: Sunday, April 6, 2014 Time: 1pm – 5pm Pacific Session Title: Biomarkers of Tumor Metastasis Title: Identification of Genomic Alterations Associated with Metastasis in Clear Cell Renal Cell Carcinoma The study, conducted by Cancer Genetics in collaboration with researchers from Memorial Sloan-Kettering Cancer Center, was designed to identify genomic copy number alterations by a high-resolution approach (whole genome array-CGH) that could serve as biomarkers for tumor metastasis in clear cell renal carcinoma.The poster highlights results from 16 significant aberrations that were identified to occur at higher frequencies in metastatic compared to primary samples across unmatched and matched analyses.The authors suggested that upon further validations, including prospective studies, such aberrations could serve as biomarkers of metastatic disease and, therefore, could be helpful in risk-stratification and clinical management of low stage ccRCC patients.Also in this study, metastatic site-specific aberrations were identified that could be useful in defining subclinical disease and to help understand the biology of those metastasis. Clear Cell Renal Cell Carcinoma accounts for approximately 70% of all renal cortical neoplasms.Metastatic ccRCC is well known for its aggressive nature and poor prognosis, with approximately 20-40% of patients relapsing within 5 years of nephrectomy.Also, metastatic ccRCC is largely refractory to conventional treatments with a five-year survival rate of approximately 8-9%, whereas targeted therapies are proven to increase overall survival rates.Treatment options vary depending on the site of metastasis. This is the first year Cancer Genetics will have a presence at AACR. Company representatives will be located at Booth #445. Cancer Geneticsis alsotheprimarysponsor of the Society of American Asian Scientists in Cancer Research annual dinner meeting, to be held on April 6that The San Diego Woman's Clubat 6pm Pacific Time.Approximately 500 scientists, clinicians and researcherswill gather to present awards to the five top scientists, researchers and contributors to cancer research. About Cancer Genetics: Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com. Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements. CONTACT: Investor Relations Michael Rice Life Science Advisors LLC 646-597-6979 Media Relations RedChip Companies, Inc. Paul Kuntz, 800-733-2447, ext. 105 firstname.lastname@example.org
Cancer Genetics to Present New Data From Renal Cell Carcinoma Study at AACR
Press spacebar to pause and continue. Press esc to stop.